USPTO Deadlines
Application History
24 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Oct 21, 2011 | UNDN | O | UNDELIVERABLE MAIL - NO ACTION TAKEN | Loading... |
Oct 3, 2011 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
Oct 3, 2011 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
May 5, 2011 | WOAR | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED | Loading... |
May 5, 2011 | WOAG | I | WITHDRAWAL OF ATTORNEY GRANTED | Loading... |
Mar 12, 2011 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Mar 11, 2011 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
Mar 11, 2011 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
Mar 1, 2011 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Mar 1, 2011 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
Sep 2, 2010 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Aug 31, 2010 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Aug 31, 2010 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
Aug 31, 2010 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
Mar 2, 2010 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Dec 8, 2009 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Dec 8, 2009 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Nov 3, 2009 | ALIE | A | ASSIGNED TO LIE | Loading... |
Nov 3, 2009 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
Oct 19, 2009 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Oct 19, 2009 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Jul 22, 2009 | MPMK | O | NOTICE OF PSEUDO MARK MAILED | Loading... |
Jul 21, 2009 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Jul 21, 2009 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Detailed Classifications
Class 005
medical diagnostic and therapeutic preparations for clinical use, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold as a kit, namely, inhalers; medical preparations, namely, nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasconconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ARDS), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (SVT), adenosine stress tests, infantile respiratory distress syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, eg, cancers which metastasized to the lung(s), breast, liver and prostate
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Design Mark
The mark consists of The mark consists of stylized letter "E" connected to another transposed stylized letter "E" in a top to bottom alignment.
Color Claim
Color is not claimed as a feature of the mark.
Pseudo Mark
EPIGENESIS
Classification
International Classes
005